Jiong Wu
Fudan University
Emerging Leaders
not ranked
Current Leaders
#3546 pts
All-Time Leaders
#37229 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2013. 13 trials as lead/chair. How it works →
Trials led — by scientific impact
A Multicenter, Randomized, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC)
Phase 3RecruitingBiotheus Inc.Study Chair
10
impact
A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20089 in Patients With Advanced Solid Tumors
Phase 1RecruitingShanghai Hansoh Biomedical Co., Ltd
5
impact
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.
4
impact
Comparison of Patient-Reported Outcome and Safety Outcomes Between Preoperative and Postmastectomy Radiotherapy in Breast Cancer Patients with Reconstruction of DIEP Flap: a Multicenter，Prospective，Open-label，Randomized Controlled Trial
N/ARecruitingFudan University
3
impact
A Randomized, Controlled Phase Ⅲ Study of Paclitaxel Polymeric Micelles for Injection Versus Physician's Choice(TPC) in Human Epidermal Growth Factor Receptor 2-negative (HER2-) Metastatic Breast Cancer (MBC) Subjects Who Have Failed at Least Two Previous Chemotherapy Regimens.
Phase 3RecruitingShanghai Yizhong Pharmaceutical Co., Ltd.
3
impact
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial Of JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Phase 3RecruitingJiangsu Alphamab Biopharmaceuticals Co., Ltd
2
impact
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody Combination Therapy in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.
2
impact
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumor
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.
1
impact
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of SI-B003 Monotherapy or BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.
1
impact
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure
Phase 3ActiveSichuan Baili Pharmaceutical Co., Ltd.
0
impact
Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Phase 2ActiveJiangsu Alphamab Biopharmaceuticals Co., Ltd
0
impact
A Multicenter Prospective Observational Cohort Study of Breast Cancer Based on a Breast Cancer Medical Record Database in China
N/ARecruitingFudan University
0
impact
0
impact
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in Patients With Early-stage or Locally Advanced HER2-positive Breast Cancer
Phase 2UnknownJiangsu Alphamab Biopharmaceuticals Co., Ltd
0
impact
A Prospective Randomized Multicenter Phase III Study of Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node--the Validation of Z0011 in China
Phase 3WithdrawnShandong Cancer Hospital and Institute
0
impact